The primary challenge in combining KRAS inhibitors with immunotherapy is managing toxicity. A severe side effect could force discontinuation of both drugs, thereby sacrificing the potential for a long-term cure from immunotherapy alone. The goal is to avoid trading overall survival for a higher initial response rate.

Instead of starting all three drugs in a triplet combination simultaneously, a more effective clinical approach is to introduce them sequentially. By starting one drug, then adding the second, and finally the third over a period of weeks or months, clinicians can more easily identify the source of any toxicities, leading to better management and improved patient compliance.

An ADC may show better response rates than chemotherapy, but its true benefit is compromised if toxicities lead to treatment discontinuation. As seen with failed PARP/IO combinations, if patients cannot tolerate a drug long enough, the regimen's overall effectiveness can become inferior to standard therapy.

The failure of the TROPiCS-04 trial for sacituzumab govitecan may not indicate the TROP2 ADC class is ineffective. Experts suggest problems with dosing and toxicity management (e.g., neutropenia) during the trial could be the real culprit, arguing that the drug class still holds promise.

Contrary to the assumption that two drugs are always more toxic than one, the Lenvatinib-Belzutifan combination in the LightSpark-011 trial presented a different, but not quantifiably worse, toxicity profile compared to cabozantinib monotherapy, challenging conventional thinking on combination therapy side effects.

Previous adjuvant trials in kidney cancer using more toxic VEGF-TKIs largely failed. Belzutifan's success suggests that in the adjuvant setting, a drug's tolerability and the ability for patients to maintain dose intensity are more critical for efficacy than raw potency in advanced disease. TKIs were often too toxic for patients to endure for a full year.

Despite massive unmet need, drug development in higher-risk MDS has stalled because many drugs promising in Phase 1/2 trials fail in Phase 3. Their toxicities, manageable in smaller trials, become prohibitive for the older, co-morbid patient population in larger studies, making a favorable safety profile a critical prerequisite for success.

The TRILINX trial revealed Xevinapant's toxicity was so high that it forced reductions in standard, effective treatments like cisplatin and radiation. This compromised the foundational therapy, leading to worse patient outcomes and demonstrating a key risk in adding novel agents to established regimens.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.